DOVA PHARMACUET (NASDAQ:DOVA) shares reached a new 52-week high during trading on Friday after an insider bought additional shares in the company. The company traded as high as $24.06 and last traded at $24.27, with a volume of 49,281 shares. The stock had previously closed at $23.32.
Specifically, VP Kevin Laliberte acquired 6,200 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $105,400.00. Following the completion of the acquisition, the vice president now owns 6,200 shares of the company’s stock, valued at approximately $105,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Alex Sapir purchased 20,100 shares of the firm’s stock in a transaction on Wednesday, July 5th. The shares were purchased at an average price of $17.00 per share, with a total value of $341,700.00. Following the completion of the acquisition, the chief executive officer now directly owns 20,100 shares of the company’s stock, valued at $341,700. The disclosure for this purchase can be found here. Insiders acquired 101,800 shares of company stock valued at $1,798,280 over the last 90 days.
The company’s market cap is $597.26 million.
WARNING: “DOVA PHARMACUET (DOVA) Hits New 52-Week High on Insider Buying Activity” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thestockobserver.com/2017/07/18/dova-pharmaceuticals-inc-dova-reaches-new-52-week-high-on-insider-buying-activity-updated.html.
About DOVA PHARMACUET
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for DOVA PHARMACUET Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DOVA PHARMACUET and related companies with MarketBeat.com's FREE daily email newsletter.